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ALKBH overexpression in head and 
neck cancer: potential target for 
novel anticancer therapy
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ewa Migacz2, Dominika Wołosz4, Damian Mielecki1, Arne Klungland5, Jan piwowarski1, 
Jarosław poznański  1 & Elżbieta Grzesiuk1
The nine identified human homologues of E. coli AlkB 2-oxoglutarate (2OG) and Fe(II)-dependent 
dioxygenase, ALKBH1-8 and FTO, display different substrate specificities and diverse biological 
functions. Here we discovered the combined overexpression of members of the ALKBH family in 
head and neck squamous cell carcinomas (HNSCC). We found direct correlation of ALKBH3 and FTO 
expression with primary HNSCC tumor size. We observed unidentified thus far cytoplasmic localization 
of ALKBH2 and 5 in HNSCC, suggesting abnormal role(s) of ALKBH proteins in cancer. Further, high 
expression of ALKBHs was observed not only in HnScc, but also in several cancerous cell lines and 
silencing ALKBH expression in HeLa cancer cells resulted in dramatically decreased survival. considering 
the discovered impact of high expression of ALKBH proteins on HnScc development, we screened for 
ALKBH blockers among newly synthetized anthraquinone derivatives and demonstrated their potential 
to support standard anticancer therapy.
Head and neck squamous cell carcinomas (HNSCC) include a variety of tumours of different epidemiology and 
ethology, originating in the oral cavity, hypopharynx, nasopharynx, oropharynx, or larynx. HNSCC is the seventh 
most common malignancy worldwide, responsible for approximately 400 000 deaths per year1 In cancer tissues 
increased dynamic of metabolic processes result in high level of nucleic acid modifications and in consequence, 
induction of DNA repair systems2,3. These system expression leads to the removal of DNA lesions before they 
become toxic to the rapidly dividing cancer cell, ensuring tumour welfare and creating a major mechanism of 
resistance to anticancer therapy3.
In Escherichia coli, AlkB (EcAlkB) protein is a prototypical, one-protein DNA/RNA repair system, part of the 
so-called “adaptive response”. It is the best known member of the 2-oxoglutarate (2OG) and Fe(II)-dependent 
dioxygenase superfamily4. The human genome encodes nine EcAlkB homologs: ALKBH 1-8 and FTO (fat mass 
and obesity associated protein)5. They fulfil a variety of biological functions, such as DNA repair, involvement in 
the metabolism of different RNA species, histone demethylation, acting as methyltransferases or taking a part in 
fatty acid metabolism6.
Overexpression of individual ALKBH proteins has been detected in overwhelming majority of various types 
of cancer7, suggesting a pro-carcinogenic role of these proteins (Table 1), e.g. FTO overexpression correlates with 
increased cancer cell survival in breast cancer, under the conditions of glutamine deficiency8. Likewise, Alkbh2 
knockdown in bladder cancer tissue limited tumour development, while ALKBH2 down-regulation sensitized 
cells to alkylating agents in glioma9,10 and cisplatin in lung cancer11. Considering these findings, inhibitors of 
ALKBH proteins could act as anticancer substances. The group of anthraquinones, including rhein and emodin, 
is particularly promising because these compounds exhibit anti-inflammatory, anti-bacterial, and anti-cancer 
properties12. Moreover, rhein has been shown to inhibit EcAlkB, ALKBH 2, 3, and FTO activity13,14.
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For the first time, we detected overexpression of a majority of the ALKBH proteins in clinical HNSCC samples 
and high levels of expression in several cancer cell lines. Importantly, some of the proteins changed localization 
in cancer cells, indicating specific function in different cell compartments, and correlated with clinical tumour 
parameters. Finally, we modified emodin to improve its inhibitory effect against ALKBHs and show anticancer 
activity of some of the new derivatives obtained on different cancer cell lines.
Results
expression of ALKBH proteins correlates with HnScc development. ALKBH levels are increased 
in HNSCC. The clinicopathological characteristics of the 41 patients are shown in Table 2. The table includes 
main data concerning patients, TNM tumour parameters, and other diseases.
Using western blot (WB) analysis, we detected overexpression of seven out of the nine ALKBH proteins 
(ALKBH1, 2, 3, 4, 5, 8, and FTO) in HNSCC cancer tissues, as compared to the surrounding, unaffected tissue 
(Figs 1A and S1–7). The expression of ALKBH 6 and 7 was not detected by our WB method. We used TET2 diox-
ygenase expression as the negative control and observed that it was expressed at equal levels in cancer and normal 
tissue (data not shown). The highest expression levels were observed for ALKBH4, 5, and FTO (Fig. 1C). Further 
analysis indicated that, among overexpressed ALKBH proteins, the greatest difference between tumour and sur-
rounding tissue was observed for ALKBH2 (5-fold), FTO (4-fold), ALKBH1 (3-fold), and 5 (2-fold) (Fig. 1D). 
Thus, simultaneous overexpression of the indicated dioxygenases in cancer tissue may be used in cancer diagnosis 
as a meta-marker. Towards this aim, the best candidates are ALKBH1 and FTO, according to receiver operating 
characteristic (ROC), where false positive rate were below 26% (Fig. S8).
Analysing the levels of ALKBHs in HNSCC tumours, we observed the simultaneous increase in expression of 
at least four ALKBH proteins in approx. 88% of patients and at least five ALKBHs in over 50% of patients. More 
than 25% of patient samples tested showed high expression of all seven ALKBH proteins (Fig. 1E). This implicates 
similar substrate specificity and/or common regulation of these proteins. To find out if ALKBH overexpression is 
a common phenomenon in cancer cells, we also assessed expression of ALKBH proteins in various cancerous cell 
lines: HeLa (cervix), U87 (brain), BICR 18 (larynx), Jurkat E6-1 (peripheral blood) and H929 (bone marrow), and 
embryonic HEK293 (kidney). As a model of normal tissue we used EUFA30 (fibroblast) (Fig. 1B). In almost all 
of the cancerous cell lines—despite different origin—we observed expression of all of the ALKBH proteins tested. 
The highest expression of ALKBH proteins was detected in HeLa, Jurkat, H929, and HEK293, while the lowest 
was detected in BICR18 and EUFA30, the control.
Correlation between the levels of expression of ALKBH proteins. Next, we assessed the relation-
ship between the expression levels of individual ALKBHs protein in normal surrounding tissue and in HNSCC 
(Fig. 2A,B). In the healthy periphery, we identified three correlated pairs, with the highest Spearman’s rank cor-
relation coefficients (ρ > 0.55, p < 10−3) calculated for ALKBH5-FTO, ALKBH1-FTO, and ALKBH3-ALKBH5 
pairs. In the cancer tissue, we observed a similar correlation involving ALKBH5-FTO, ALKBH3-ALKBH5, and 
ALKBH1-ALKBH5, but also noted that the level of ALKBH2 was correlated with that of ALKBH5 and ALKBH1 
with ALKBH3.
To investigate further these correlations, we used small interfering RNA (siRNA) for ALKBH1, 2, 3, 4, 5, 
FTO genes and using WB analysis, we recognized the expression levels of ALKBH1, 3, 5 and FTO (Fig. 2C). The 
HeLa cells were chosen as highly expressing the ALKBH proteins. In the case of ALKBH2, 4, and 8 genes, their 
silencing led to the downregulation of almost all ALKBHs tested. Silencing of ALKBH1 or FTO did not influence 
the level of the investigated proteins. Interestingly, only in two cases we observed the opposite effect, namely, 
ALKBH8 silencing led to the elevated level of ALKBH1, while FTO silencing increased ALKBH5 level. Moreover, 
we noticed downregulation of ALKBH3 and FTO after the silencing of ALKBHs in the most cases.
Cancer
PROTEIN
CitationALKBH2 ALKBH3 ALKBH5 ALKBH8 FTO
Prostate ↑ 40
Renal ↑ 41
Bladder ↑ ↑ ↑ 10,42,43
Rectal ↑ 44
Lung ↑ 45
Gastric ↓ ↑ 46,47
Pancreas ↑ 48
Endometrial ↑ 49
Breast ↑ ↑/↓ 7,50,51






Table 1. Expression of ALKBHs in individual type of cancer.
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ALKBH3 and FTO levels are related to the clinical tumour parameters. In order to assess the rela-
tionship between ALKBH level and cancer progression, we compared protein expression levels with tumour 
parameters. We detected significantly higher levels of ALKBH3 and FTO in larger primary tumours (type T4 
in TNM classification), as compared to smaller ones (type T2 in TNM classification) (Fig. 3A). Interestingly, 
in type T2 tumours, the level of ALKBH3 was similar or slightly higher than in adjacent tissue, whereas in type 
T4 tumours ALKBH3 level was strongly elevated in comparison to unaffected surrounding tissue. Meanwhile, 
increased levels of FTO were observed in all examined groups (Fig. 3C). Thus, the content of ALKBH3 and FTO 
increases along with the tumour size. We did not observe any other correlations between tumour size or primary 
tumour extension and the other ALKBH proteins; ALKBH levels were not correlated with tumour invasiveness 
(G parameter), metastasis (N parameter), or TNM stage (Fig. 3A). Finally, we assessed the impact of ALKBH 
expression level on HeLa viability. Using siRNA, we silenced single/double ALKBH proteins and found that 
silencing ALKBH1, 4, 5, and FTO significantly influenced cell viability (Fig. 3D). On the other hand, silencing 
ALKBH2, 3, 8 and the combined silencing of ALKBH2 and 3 did not influence cell viability.
When silencing performed in EUFA30, HeLa, and Jurkat cell lines with siRNAs targeted towards selected 
ALKBHs, we observed that downregulation of ALKBH1, 4, or FTO slightly promoted necrosis in HeLa cells to the 
values of 25.5, 21.7, and 30.6%, respectively (Fig. 3E). On the other hand, Jurkat cells did not show any sensitivity 
to siRNAs used. Although in EUFA30 cells, ALKBH1 and FTO siRNAs induced apoptosis (9 and 7%, respec-
tively), the levels of cell viability were still in the range of the control.
Elevated level of RNA N6-methyladenosine in HNSCC. Having discovered high level of ALKBH pro-
teins in HNSCC, we decided to assess the level of N6-methyl-adenosine (N6meA), the most abundant RNA modi-
fication in eukaryotic cells and the substrate for FTO and ALKBH5 proteins. Surprisingly, despite high expression 
of FTO/ALKBH5 in cancer tissue, the level of N6meA was also significantly elevated, in comparison to normal 
tissue (Fig. 4A). Nevertheless, we observed a great deal of variation in the FTO/ALKBH5 vs N6meA ratio in indi-
vidual patients (Fig. 4B).
Characteristic N (%) or mean [IQR]
Age 59 [53.5-68.5] T classification
Weight 73 [58.5-82] Unknown 10 (24%)
BMI 25 [20.5-27.9] 1 1 (2%)
Sex 2 12 (29%)
Male 29 (57%) 3 13 (32%)
Female 12 (24%) 4 5 (12%)
Unknown 10 (20%) N classification
Tumor location Unknown 8 (20%)
Neck 5 (12%) 0 18 (44%)
Larynx 29 (71%) 1 4 (10%)
Tongue 3 (7%) 2 10 (24%)
Other 4 (10%) 3 1 (2%)
Grading M classification
Unknown 7 (17%) Unknown 10 (24%)
1 1 (2%) 0 31 (76%)
2 25 (61%) TNM stage





Other diseases N (%)
Jaundice Asthma Hypertension Problems with blood coagulation
Yes 1 (2%) Yes 2 (5%) Yes 5 (12%) Yes 0 (0%)
No 20 (49%) No 20 (49%) No 17 (41%) No 22 (54%)
Unknown 20 (49%) Unknown 19 (46%) Unknown 19 (46%) Unknown 19 (46%)
Internal organs 
diseases Peptic ulcers Diabetes Viral hepatitis
Yes 1 (2%) Yes 1 (2%) Yes 3 (7%) Yes 1 (2%)
No 20 (49%) No 21 (51%) No 18 (44%) No 22 (54%)
Unknown 20 (49%) Unknown 19 (46%) Unknown 20 (49%) Unknown 18 (44%)
Table 2. Clinicopathological features of HNSCC patients included in this study (n = 41).
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the cellular localization of ALKBHs in HnScc cells. Confocal microscopy analysis was used to exam-
ine any changes in the subcellular localization of ALKBH proteins in HNSCC cells, as compared to the nor-
mal, surrounding tissue (Table S1). For ALKBH1, 4, 8, and FTO we observed the expected, previously-described 
localization. However, for ALKBH2 and 5, we found that these nuclear proteins were also highly expressed in 
cytoplasm. Additionally, we observed that ALKBH3 was expressed only in cytoplasm (Fig. 5). These changes in 
protein localization suggest that ALKBHs may play different roles in cancer and normal cell metabolism.
Design of ALKBH inhibitors
The western blot analysis and immunofluorescence on clinical HNSCC samples and RNA interference in human 
cell line indicate the involvement of ALKBH proteins in cancer survival and growth. As a result, the ALKBH 
inhibitors may offer a new approach to anticancer therapy. Towards this aim, we performed molecular modelling 
of ALKBH proteins with a set of selected antraquinones with proven anti-cancer activity, as well as newly synthe-
tized chloro-derivatives.
In silico modelling of the ALKBH - anthraquinone (enzyme-ligand) complexes. Because no struc-
tures of the proper forms of holoenzyme complexes with anthraquinone derivatives are accessible in PDB 
(Fig. S9), we performed in silico screening for all ALKBH proteins by means of homology modelling, followed 
by molecular docking. The binding affinities estimated for 60 various complexes of the ten ALKBH proteins 
(ALKBH1-8, FTO, and EcAlkB) with six anthraquinone derivatives ranged from 0.02 to 10 μM (Fig. 6A). EcAlkB 
Figure 1. ALKBH expression in HNSCC and indicated cell lines: (A) WB analysis of ALKBH expression in 
HNSCC samples. siRNA - HeLa cells treated with siRNAs directed towards particular ALKBHs; Cont. - HeLa 
cells not treated by siRNA; Nor - normal periphery; Can- cancer; A-F - tumour samples. (B) WB analysis of 
ALKBH expression in various cell lines: normal, cancer and embryonic. (C) ALKBHs expression in cancer and 
normal tissues from HNSCC patients. Samples were classified into three groups according to the expression 
level of each protein: (i) stronger signal from cancer than normal surrounding; (ii) weaker signal from cancer 
than normal surrounding; (iii) no detectable expression of the proteins in the normal and cancer tissue. 
N – number of patients; p - p-value obtained from the Wilcoxon signed-rank test for paired samples. (D) 
Nonparametric Wilcoxon rank-sum test (for groups) were performed. n- number of samples from each group; 
P-values with Benjamini-Hochberg adjustment: *p < 0.025; **p < 0.005; ***p < 0.0005; ****p < 0.00005; 
*****p < 0.000005. (E) Heat map of changes of individual protein expression in HNSCC. Fold changes were 
calculated for tumour vs. adjacent normal tissue. White - no detectable expression of particular protein in 
cancer and adjacent tissue. Blue - decreased relative protein level. Orange - increased relative protein level. Grey 
- no data gathered.
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and FTO were the most preferred targets for all ligands, ALKBH2 and ALKBH3 were clearly less preferred, while 
the remaining six proteins did not bind the tested anthraquinones (Kdiss > 1 μM). These results are in agreement 
with previous experimental data demonstrating that rhein inhibits bacterial EcAlkB and eukaryotic ALKBH 2, 
3, and FTO proteins13,14.
The structure of the FTO-rhein complex was close to that accessible in PDB, but the ligand was placed deeper 
at the binding site (RMSD < 2 Å). In contrast to ALKBH3—for which the carboxyl group of rhein interacts with 
Arg118 and Arg131 (Fig. S10) — no salt-bridges were identified for FTO-ligand interactions; thus, not surpris-
ingly, 7-chloroemodin was found to be the best ligand, whereas emodin and 5-chloroemodin scored slightly lower 
(Figs S11 and S12).
Impact of anthraquinones on stability and enzymatic activity of AlkB, ALKBH3, and FTO. We 
tested the affinity of our newly synthesized anthraquinones, 7-chloroemodin and 5,7-dichloroemodin, (Fig. S13) 
for ALKBH3 and FTO and assessed their effect on the enzymatic activity of targeted proteins using the thermal 
shift assay (TSA). The thermodynamic parameters for thermal denaturation of both proteins were measured for 
their holo forms, in the presence of 2OG and Mn2+, an analogue of Fe2+.
The strongest ligand for ALKBH3 was rhein (Figs 6B and S14A), because its addition increased the melting 
temperature the most. Emodin, aloe-emodin, and 5,7-dichloroemodin bound to ALKBH3 slightly more weakly.
All of the tested ligands increased the melting temperature of the FTO holo form (52.8 ± 0.6 °C) by more than 
10 °C (Fig. 6C). The most pronounced effect was observed for 7-chloroemodin and 5,7-dichloroemodin, with 
these complexes melting at 71.5 ± 0.2 °C and 67.4 ± 0.1 °C, respectively.
For EcAlkB, ALKBH3, and FTO, the inhibitory effect was further quantified by measuring inhibition of 
demethylation activity in vitro (Fig. 6D). We used 3-methylcytosine (3meC) on TT(3meC)TT pentamer as a 
substrate and the anthraquinones listed in Fig. 6D as inhibitors. The best EcAlkB inhibitors were 7-chloroemodin 
and 5,7-dichloroemodin, with IC50 of 19.8 μM and 16.4 μM, respectively, followed by rhein with IC50 of 20.5 μM. 
The remaining anthraquinones displayed at least 10-fold lower activity. Enzymatic activity assay also confirmed 
that rhein is the best inhibitor of ALKBH3, with IC50 of 40 nM (Fig. S14). Aloe-emodin displayed lower activity 
Figure 2. Relationships between protein levels within ALKBH family members. (A) Relationship between the 
levels of ALKBH proteins in healthy surrounding tissue and (B) HNSCC tumour. Each tabulated entry presents 
the Spearman’s rank correlation coefficient and indicates the p-value of correlation. Hierarchical cluster analysis 
of matrices presents similarities between examined ALKBHs. P-values with Benjamini-Hochberg adjustment: 
‘p < 0.005; *p < 0.0025; **p < 0.0005; ***p < 0.00005; ****p < 0.000005. (C) Impact of individual ALKBH 
protein silencing on expression of its homologs in HeLa. Silencing was done with the use of small interfering 
RNA, ALKBH protein levels were measured by WB.
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Figure 3. Relationship between ALKBH proteins level and tumour parameters and cancer cell viability. (A) 
Analysis of variance (ANOVA) of ALKBH protein levels in HNSCC tumours. Each tabulated entry shows 
F-value and p-value of F-test, providing information on the effect of the level of the particular ALKBH protein 
on the specific tumour parameter: G – tumour invasiveness, T, N, M - The Union for International Cancer 
Control (UICC) parameters. The sample size for ALKBH2 and ALKBH8 was too small to execute ANOVA 
with other ALKBH proteins, a separate analysis was performed for these two proteins. (B,C) Relationship 
between selected ALKBH protein and tumour size. P-values with Benjamini-Hochberg adjustment: *p < 0.05, 
***p < 0.001. (D) Survival assay of HeLa cells treated with siRNA for a given ALKBH protein. HeLa cell 
viability was assessed 48 h after treatment. P-values with Benjamini-Hochberg adjustment: ****p < 0.0001. (E) 
Flow cytometry analysis of EUFA30, HeLa, and Jurkat cells stained with Annexin-FITC and propidium iodide. 
Cells were treated with 34 nM of siRNA on ALKBH1, 4, or FTO for 48 h.
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(IC50 8.8 μM) and the other anthraquinones were inactive (IC50 > 100 μM). For the case of FTO, activity that was 
monitored using N6meA demethylation assay and rhein was the most efficient inhibitor with IC50 of 7.1 μM, 
followed by 7-chloroemodin with IC50 of 28.1 μM, which was more active than emodin. In summary, rhein, 
7-chloroemodin, and 5,7-dichloroemodin are the most effective ALKBH inhibitors, but possess different affinities 
towards the individual proteins.
Cytotoxic effect of anthraquinones on normal and cancer cells. We evaluated the cytotoxic efficacy of 
the compounds under study, on cancerous HeLa, U87, BICR18, embryonic HEK293, and normal EUFA30 cells 
(Fig. 7A). We found that emodin is the most cytotoxic among all natural anthraquinones tested. Moreover, it is 
more toxic to cancerous than healthy cells. The IC50 values for emodin were 110.1, 42.7, and 81.1 μM for HeLa, 
U87, and BIRC18, respectively. Its therapeutic index (TI) varied from 1.25 to 3.2. Within newly synthetized com-
pounds, 5,7-dichloroemodin was the most potent, with IC50 equal to 10.6 and 39.8 μM and a therapeutic indexes 
of 9.6 and 2.6 for HeLa and BICR18, respectively. Summarizing, emodin and 5,7-dichloroemodin showed higher 
cytotoxicity against cancerous than healthy cell lines. Noteworthy, the biggest therapeutic indices, equal 14.6 μM, 
showed aloe-emodin against HeLa cells. Unfortunately, this compound was not cytotoxic against HEK293 and 
U87 cell lines. Additionally, HeLa cells were less resistant to anthraquinones.
Apoptosis induction after rhein, emodin, 7-chloremodin, and 5,7-dichloroemodin treatment was assessed 
using flow cytometry in normal (EUFA30) and cancerous cell lines (HeLa, Jurkat) (Fig. 7B). EUFA30 cells were 
more sensitive to natural anthraquinones, rhein and emodin, than to the newly synthetized derivatives: after 
treatment with 500 μM rhein, early apoptosis stage increased approximately 2-fold, late apoptosis 15-fold, and 
necrosis increased 11-fold, compared to untreated control (Fig. 7B). HeLa cells were much more sensitive to 
7-chloroemodin and 5,7-dichloroemodin than EUFA30. The number of necrotic HeLa cells increased to 69.2% 
and 83.1%, in the presence of 25 μM and 100 μM 5,7-dichloroemodin, respectively. For 7-chloroemodin, the 
respective values were 18.8% (for 25 μM) and 37.6% (for 100 μM), as compared to 10.8% in the case of untreated 
control. Emodin showed similar effect as anthraquinone derivatives, but also promoted late apoptosis. Overall, 
Jurkat cells were the least sensitive. Interestingly, anthraquinones cause mostly apoptosis in EUFA30 and Jurkat 
cell lines, while necrosis prevails in HeLa.
In summary, the natural anthraquinone emodin and our novel derivative 5,7-dichloroemodin demonstrate 
promising potential as inhibitors for anticancer therapy.
Figure 4. The level of N6meA in cancer and normal tissue. (A) For pairs, nonparametric Wilcoxon signed-
tank test was performed. n - paired number; *p < 0.05; Nor- normal periphery; Can- cancer. (B) Comparison 
of relative expression levels of ALKBH5, FTO and N6meA. Deeper colours represent higher level of ALKBH5 
(blue), FTO (green) or N6meA (red).
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Discussion
In the last decade, the family of AlkB dioxygenases has been extensively studied, especially in the context of new 
substrates, but also in terms of their role in the development of so-called “diseases of affluence”, including obesity, 
type-2 diabetes, cancer etc. Several recent publications have reported increased levels of individual ALKBHs in 
various types of human cancer (Table 1). Here we demonstrated that in HNSCC, the expression level of seven 
out of nine ALKBHs (1, 2, 3, 4, 5, 8, and FTO) was significantly increased in 68-90% of the samples. This shows, 
Figure 5. ALKBH proteins expression in the HNSCC tissue in II stage accordingly to TMN stale visualized 
using confocal microscopy. Cell nuclei staining by Hoechst 3558 visualized as blue fluorescence (nuklei panel), 
ALKBH proteins expression was visualized using specific primary antibodies and secondary antibody conjugate 
with AlexaFluor 568 as red fluorescence (protein expression panel), merge (merge panel), transparent view 
of unstained tissue (unstained protein panel). Objective 20x. Additional zoom (2.5x) of part of view marked 
by white frame was performed to visualized cellular localization of ALKBH proteins in single cell. Basic 
microscope settings were as follows: scan layer = 200 μm; kalman = 8; offset = 0%, scanning: sequential for each 
channel: for Alexa Fluor 568 - green laser (HeNe 543 nm); for Hoechst 3558 (UV Ar, 351 nm).
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for the first time, that not just one single ALKBH, but the whole group of ALKBH proteins is overexpressed 
in HNSCC tumours. At least four different ALKBH proteins were highly expressed in 88% of tested tumours 
and in 25% of cases, all seven proteins were overexpressed. We found highly expressed ALKBH proteins in sev-
eral cancerous cell lines, suggesting that the simultaneous overexpression of several members of ALKBH family 
proteins is a common process accompanying cancerogenesis. This hypothesis is supported by the observation 
of strong co-expression of particular ALKBH pairs in HNSCC, namely ALKBH1 with 3 and ALKBH2 with 5. 
Moreover, in the case of HeLa cells, the silencing of ALKBH2, 4, or 8 genes reduced expression of other homologs 
(Fig. 2C). Keeping in mind that FTO and ALKBH5 share the same substrate specificity15,16, not surprisingly that 
the silencing of the FTO gene leads to upregulation of ALKBH5 protein. Furthermore, one can suppose that 
the ALKBHs co-express in the similar way and can be co-regulated at the expression level. Further, silencing of 
ALKBH1, 4, 5, and FTO markedly decreased HeLa cancer cell survival (Fig. 3), suggesting involvement of these 
ALKBHs in cancer development by DNA/RNA/protein modification. In contrast, silencing of ALKBH2, 3, 8 or 
both, ALKBH2 and 3, did not affect cancer cell viability. This is in agreement with prior reports showing that 
knocking down ALKBH2 or 3 did not influence mice phenotype and viability17. We can conclude that overex-
pression/co-expression of the whole group of ALKBH proteins correlates with cancer development, including its 
different types, indicated by: (i) the high expression of almost all of the ALKBHs in HNSCC and in various cancer 
cell lines; (ii) decreased cancer cell viability following ALKBHs silencing; (iii) previously reported high expres-
sion of single ALKBHs in different types of cancer; (iv) the siRNA-treated mice with developed cancer show 
diminishing tendency of cancerous tissue. Summing up, overexpression of a single or a group of ALKBH proteins 
could be used as a marker for cancer diagnosis18. The samples obtained by biopsy (or surgery) could be subjected 
to Western blot analysis and adequate chemotherapy, e.g. combination of alkylating agents and antraquinone 
derivatives, could be established.
Further, we demonstrated that ALKBH3 and FTO levels are correlated with primary tumour size (T in TNM 
classification): protein expression was higher in larger T4 tumours, as compared to smaller T2 tumours. The cor-
relation between increased FTO expression and tumour size may suggest a new regulatory role for this protein 
in tumour development. On the other hand, the high amount of the repair protein ALKBH3 present in larger 
tumours may be explained by accumulation of alkylation damage to DNA/RNA, due to metabolic instability of 
the developed cancer. We can presume that other ALKBH proteins may also promote or sustain tumour welfare, 
considering their high expression levels.
Figure 6. Design and in vitro examination of ALKBHs inhibitors. (A) Results of in silico screening for the 
binding of anthraquinone derivatives by ALKBH proteins. Molecular docking indicated that FTO and EcAlkB 
are the best targets, followed by ALKBH2 and ALKBH3, albeit each of these proteins displayed specificity 
towards particular ligands. Other ALKBH proteins virtually did not bind any of the ligands tested. (B,C) The 
results of the thermal shift assay for ALKBH3 and FTO in the presence of tested anthraquinones. ΔH - enthalpy, 
Tm - protein melting temperature. (D) Inhibitory effect of anthraquinones on EcAlkB protein and its human 
homologs.
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Interestingly, we also observed an increased global level of N6meA in HNSCC, the most abundant internal 
modification in mammalian mRNA, suggesting an abnormal methylation profile in HNSCC. N6meA is involved 
in mRNA stability, translation efficiency, splicing, RNA-protein interactions, and more15. It is also responsible for 
Figure 7. Viability assay and flow cytometry analysis for indicated anthraquinones. (A) Cytotoxic effect of 
natural anthraquinones and newly synthetized derivatives on EUFA30, HeLa, HEK293, U87, BICR18 cells after 
48 h of treatment. Table includes IC50 value (μM). Therapeutic index is provided in brackets (TI = IC50 normal 
cells/IC50 cancer cells). (B) Flow cytometry analysis of EUFA30, HeLa, and Jurkat cells stained with Annexin-
FITC and propidium iodide. Cells were treated with 250 or 500 µM rhein or 25 µM and 100 µM emodin, 
7-chloroemodin and 5,7-dichloroemodin for 48 h. CPT - camptothecin (10 µM) and H2O2 (1 mM) were used as 
positive controls.
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cancer stem cell pluripotency, cell differentiation, proliferation and metastasis19. Our findings reflect a discrep-
ancy in FTO/ALKBH5 action as the demethylase regulating N6meA level in mRNA in normal vs cancer cells. 
These findings are supported by the results of Merkeinestein group who has shown that an additional copy of 
FTO gene did not influence the global level of N6meA20. However, FTO may impact demethylation of selected 
transcripts, like in acute myeloid leukaemia where FTO plays a critical oncogenic role through demethylation 
of ASB2 and RARA mRNA (protein that are responsible for blood cell differentiation)21, also demethylation of 
RUNX1T1 (negative regulator of adicipogenesis)15, C/EBPβ (stimulator of hepatocytes and adipocytes growth)22, 
PPARγ (adipocytes differentiation)23, GAP-43 (growth of axons)24. Collectively, these findings prove that FTO is 
involved in various cancer development.
The different role of ALKBHs in normal vs cancer cells was also confirmed by the results of subcellular local-
ization using immunofluorescence. In HNSCC we observed the unexpected localization of nuclear proteins 
ALKBH2 and 5 in the cytoplasm, while ALKBH3 was found only in cytoplasm. These changes in subcellular 
localization suggest that these proteins can be involved in new, unknown functions that may be connected with 
tumour growth. Further, changes in localization of the remaining ALKBH proteins may be the result of a specific 
pathological state and can be taken under consideration as a prognostic marker for cancer transformation25.
The relatively high expression of ALKBHs in tumor tissues correlate with cancer development26,27 making 
these proteins the potential targets for anticancer therapy. We focused on natural antraquinones as inhibitors of 
ALKBHs and to improve the solubility and the inhibitory effect of these compounds, we substituted hydrogen(s) 
with chloride(s) atoms in emodin. Molecular docking analysis and in vitro activity assay revealed that all tested 
antraquinones strongly interact with EcAlkB, FTO, ALKBH2, and ALKBH3. Rhein shows the strongest inhibi-
tory effect among compounds under study; however, emodin and newly synthetized 5,7-dichloemodin were the 
most toxic against cancer cell lines. These data are in agreement with the results published by Li and co-workers 
(2016), who established the IC50 values for rhein against EcAlkB and ALKBH3 were 12.7 and 5.3 μM, respec-
tively14. Similarly to our observation, the authors did not found any cytotoxic effect of rhein against U87 cells. 
Chen and co-workers (2012) calculated the rhein IC50 against FTO protein activity in the range of about 30 μM13. 
The similar results were obtained by Wang and co-workers, where emodin has shown higher cytotoxic effect than 
rhein on human proximal tubular epithelial HK-2 cell line, and only emodin induced apoptosis28. On the other 
hand, the facts that Jurkat cells, although expressing ALKBHs at higher level than HeLa cells, were more resistant 
to antraquinones, and that EUFA30 cells poorly expressing ALKBHs were least sensitive imply that the emodin 
derivatives act not only by ALKBHs inhibition but also interfere with other metabolic pathways. The assessment 
of apoptosis/necrosis in EUFA30, HeLa, and Jurkat cells treated with siRNAs directed towards selected ALKBHs 
confirmed that at least, but not last, the inhibition of the dioxygenases studied leads to cell death, since the only 
visible impact of siRNAs could be observed in the case of HeLa cells, similarly to the results shown for anthraqui-
nones. If this were not the case, the Jurkat cells would be more sensitive than HeLa. Indeed, it was shown that 
rhein and emodin also interact with other proteins. Emodin inhibits VEGFR2, PI3K, and p-AKT expression in 
colon colorectal HCT116 cells29. Moreover, emodin inhibits tumor necrosis factor alpha-induced calcification 
via the NF-kB pathway30. Additionally, rhein influences cytoskeleton regulation, protein folding, or transcription 
control in breast cancer MCF-7 cell lines31. Also, the synergistic way of action cannot be excluded.
After the anthraquinone treatment, we observed mainly apoptosis in EUFA30 and Jurkat cells, and necrosis 
in HeLa cells. Varela-Ramirez and co-workers (2011) obtained similar results testing diphenylmethyltin chloride 
(DPMT) on various cell lines. They observed that DPMT induces necrosis (more than 40% of cells) on HeLa cells 
and mostly apoptosis on Kit-225 (human T lymphoma) or EL4 (murine T lymphoblastic)32.
For the first time we proved majority of human ALKBH proteins overexpress in HNSCC. Based on the key role 
of ALKBHs in HNSCC development, ALKBHs should be considered as promising new targets for the diagnosis 
and treatment of various type of cancer that exhibit high level of ALKBH proteins. In particular, the synthesis 
and use of new, more powerful ALKBH inhibitors could be a promising strategy supporting anti-cancer therapies 
based on alkylating agents. This new, modern approach could be used not only in head and neck cancers, but also 
in other types of cancer that demonstrate ALKBH overexpression.
Materials and Methods
clinical samples. 41 tissues (blinded samples) of head and neck carcinomas (29 males and 12 females) were 
collected at the Department of Otorhinolaryngology, Faculty of Medicine and Dentistry at Medical University 
of Warsaw between 2011 and 2014. 73.3% of these patients suffered from laryngeal cancer. All of the cancers 
were histologically verified as squamous cell carcinomas. The research was performed in accordance with the 
relevant guidelines and regulations. Tumours were classified according to the TNM staging system. Patients 
were not treated with chemo- or radiotherapy. Samples after histopathological examination were available in 
archives. Patients agreed to use the samples according to current procedure. Ethical Comity accepted biochemical 
tests on the samples prior to subsequent utilization according to routine procedures of biohazard. Samples were 
anonymized with no access to patient personal data. The clinicopathological data are presented in Table 2.
tissue samples and western blot analysis. Frozen samples were homogenized in liquid nitrogen and 
extracted with RIPA buffer (Sigma-Aldrich) supplemented with 50 mM EDTA and 4 mM PMSF in the pres-
ence of protease inhibitor cocktail (Sigma-Aldrich). Cellular debris was spun down and supernatant protein 
content was measured using the Bradford assay (Bio-Rad). Samples were diluted with SDS-PAGE loading buffer 
to a protein concentration of 3 μg/μl and 10 μl was loaded onto Mini-PROTEAN TGX 4-15% gradient gels 
(Bio-Rad). The western blot analysis was performed with specific primary monoclonal and polyclonal antibodies 
used at dilutions: 1:200-500 against ALKBH1, ALKBH3, FTO (Santa Cruz Biotechnology), ALKBH2, ALKBH5, 
ALKBH6, ALKBH7, ALKBH8 (Sigma-Aldrich) and ALKBH4 (Proteintech) with appropriate 1:2000 secondary 
anti-mouse IgG antibody (Sigma-Aldrich) or anti-rabbit IgG antibody (Santa Cruz Biotechnology) conjugated 
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with horse-radish peroxidase. All incubations were performed in 5% milk/PBST (PBST – phosphate buffer saline 
with 0.1% TWEEN-20). Chemiluminescence was measured using the ChemiDoc MP Imaging System (Bio-Rad). 
Total protein was standardized in four steps: (i) equal masses of the tissue were taken for extraction in RIPA buffer 
(50 mg); (ii) extract was then assayed by Bradford assay for protein content; (iii) equal amounts were loaded on 
the gel and verified by Coomassie blue staining; (iv) protein transferred to the nitrocellulose membrane was visu-
alized by Ponceau-S reversible staining prior to the final western blot. Additionally, in the case of several proteins, 
primary antibodies recognized epitopes of different molecular mass. To define which band corresponds to which 
examined ALKBH protein, we decreased the protein levels by using RNA interference.
N6meA RnA methylation assay. Frozen samples were homogenized in liquid nitrogen. Total RNA was 
extracted by TRIzol Reagent (ThermoFisher) according to the manufacturer’s protocol. Concentration and 
purity of RNA was measured spectrophotometrically by Nanodrop 2000c (ThermoScientific). Two hundred ng 
of total RNA was used in quantification of N6meA level with use of N6meA RNA Methylation Quantification 
Kit (EpiQuik). The assay was carried out according to the manufacturer’s protocol. Absorbance at 450 nm was 
measured using a scanning multiwall multimode spectrophotometer (DTX 880, Beckman Coulter). To determine 
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where: Sample A450 – Absorbance of a sample, NC A450 – Absorbance of a negative control, PC A450 – Absorbance 
of a positive control, S – Amount of RNA in a sample (200 ng), P – Amount of N6meA in a positive control 
(0.5 ng), Normedian – median of the relative N6meA level in a normal adjacent tissues.
Immunofluorescence analysis. Antigen retrieval in 5 µm rehydrated tissue sections was performed by 
boiling the slides in citrate buffer. Non-specific binding was blocked with 1% BSA/PBS at RT for 40 min. The same 
primary antibodies as those used for western blots were used at 1:50-1:200 ratio with 0.1% BSA/PBS by overnight 
at 4 °C. Secondary antibody (Thermo Fisher Scientific, AlexaFluor 568, A-11011) at a dilution of 1:100-1:400 was 
incubated at RT for 1 h. Simultaneously, incubation without primary antibodies was performed to exclude false 
immunofluorescence signal from nonspecific binding of secondary antibodies or from autofluorescence of the 
tissue. Cell nuclei were stained with Hoest 3558 at 10 μg/ml for 30 s at RT (Life Technologies). Confocal micros-
copy (Olympus FV500) with Fluoroview v5 software was used to obtain images—imaging details are provided in 
the figure legend.
Synthesis of chloroemodins. The 114 mg of emodin (0.42 mmol, 1 eq) was dissolved in 5 ml of tetrahy-
drofuran (THF) and treated with 169 mg (1.26 mmol, 3 eq) of N-chlorosuccinimide. The reaction mixture was 
stirred in RT for 18 h, then evaporated with silica gel (Silica Gel 60 M (0.040-0.063 mm, E. Merck) and purified 
by column chromatography using 5% methanol in chloroform for monochloroemodins and 20% methanol in 
chloroform for 5,7-dichloroemodin33. The following yields were obtained: 19.8 mg (15.5%) for 7-chloroemodin 
and 12.6 mg (8.8%) of 5,7-dichloroemodin.
Expression and purification of hFTO, AlkB, and ALKBH3 proteins. The plasmid with hFTO was 
constructed using StarGate cloning system (IBA Life Science) and introduced into E.coli BL-21. Bacteria were 
cultured in 37 °C to OD600 = 1, induced with 1 mM IPTG, cultured for 16 h at 16 °C, harvested, resuspended in 
PBS buffer with protein inhibitor cocktail and lysozyme. After 30 min, cells were sonicated 6 times for 30 sec 
with ultrasound (250 W). After centrifugation (20 000 x g, 10 min), the His-hFTO protein was purified using 
Ni+-Sepharose and size exclusion chromatography (Enrich SEC. 650). Purity of the protein was verified using 
SDS-PAGE. The purified protein was stored in the lysis buffer with 50% glycerol at 80 °C. Expression and purifi-
cation of AlkB and ALKBH3 dioxygenases was performed as previously described34,35.
thermal shift assays for ligand binding. The assay was developed previously to monitor ligand binding 
to AlkB36. Fluorescence experiments were performed using a Varian Cary Eclipse spectrofluorimeter. Emission 
was monitored at 345 nm (excitation at 280 nm) over a temperature range of 40-95 °C with heating rate of 1 °C/
min. The protein samples were dissolved in HEPES buffer at pH 7.5 with 2 mM dithiotreitol (DTT) and 150 mM 
NaCl to a final concentration of 1.2 µM. The process of thermal unfolding was performed at a concentration of 
5 µM of the tested compound, either in the presence or absence of cofactors (50 µM 2OG and 100 µM Mn(II)). 
The thermal unfolding of the holo form of the protein was always monitored and further used as the refer-
ence. All the calculations were performed using Origin 9.0 software, assuming the simplest model of two-state 
(Folded-Unfolded) transition.
In vitro inhibition assay. AlkB and ALKBH3. The reactions were carried out for 30 min at 37 °C in 20 µl of 
50 mM Tris-HCl pH 7.5 with 1 mM DTT, 100 µM Fe(NH4)2(SO4)2, 50 µM 2OG, and 100 nM of AlkB or ALKBH3, 
25 µM of substrate, and different concentrations of indicated inhibitors. Substrate contained 80% of TT(3mC)-TT 
and 20% TTCTT. 230 µl of ice cold water was added to stop the reaction and the mixtures were frozen to deacti-
vate the enzyme37. Modified and unmodified (repaired) products were separated and analyzed on Knauer HPLC 
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system with C18 column (Waters NovaPak). The mobile phase binding buffer (20 mM TEAA) and elution buffer 
(acetonitrile) were mixed and flown at a rate of 1 ml/min. The detection wavelength was 260 nm.
FTO. To measure the activity of obtained by us FTO protein, Chemiluminescent Assay Kit was used (BPS 
Bioscience). As a substrate, we used N6meA modification on RNA. The reactions were carried out according to 
the manufacturer’s protocol. Chemiluminescence was measured using the plate reader Synergy HT (Bio Tek) with 
1 sec of integration time and 100 ms of delay after plate movement.
cell lines. In this work following cell lines were used:
 1. EUFA30 – provided by Department of Toxicogenetis, Leiden University Medical Centre, The Netherlands; 
Passage numbers ~4;
 2. HeLa – provided by Culture Collection, Public Health England, Porton Down, Salisbury, UK (Cat. No.: 
93021013); Passage numbers ~4;
 3. HEK-293 – provided by American Type Culture Collection, Manassas, USA (Cat. No.: ATCC-CRL-1573); 
Passage numbers ~4;
 4. BICR18 – provided by Culture Collection, Public Health England, Porton Down, Salisbury, UK (Cat. No.: 
06051601); Passage numbers ~4;
 5. U-87 – provided by Culture Collection, Public Health England, Porton Down, Salisbury, UK (Cat. No.: 
89081402); Passage numbers ~4;
 6. JurkatE6-1 – provided by American Type Culture Collection, Manassas, USA (Cat. No.: ATCC® TIB-
152™); Passage numbers ~4;
 7. H929 –provided by American Type Culture Collection, Manassas, USA (Cat. No.: ATCC® CRL-9068™); 
Passage numbers ~4;
cell culture. HEK293, HeLa, U87, BICR 18, and EUFA30 cell lines were cultured in DMEM medium (Life 
Technology) supplemented with 10% fetal bovine serum (Life Technology) and 0.1% antibiotics (penicillin, strep-
tomycin, Life Technology). Cells were grown in a humidified atmosphere of CO2/air (5/95%) at 37 °C.
RNA interference of ALKBH1, 2, 3, 4, 5, 8 and FTO. Silencing was performed using the lipofectamine 
RNAiMAX reagent (Invitrogen) and ready-to-use siRNA mixture (Santa Cruz Biotechnology) composed of at 
least two different siRNAs targeting the same gene, to knock down ALKBH1, 2, 3, 4, 5, 8, and FTO (Supplementary 
Table 2). 1 × 106 cells were seeded onto a 100 mm diameter dishes. After 24 h of incubation, siRNAs mixtures 
(with lipofectamine, in OPTI-MEM medium) were added. After 48 h, cells were collected for WB or flow cytom-
etry analysis. For WB analysis, adherent cells were rinsed three times with PBS, scraped, and centrifuged (800 x g, 
10 min, 4 °C). Next, cells were re-suspended in 100 μL RIPA buffer with a 1 x mammalian protease inhibitor cock-
tail (Sigma-Aldrich). The resulting lysates were spun down at 30 130 x g to remove insoluble particles, assayed 
for protein content using the Bradford assay, and loaded onto the SDS-PAGE at the protein amount of 20 μg per 
line. The strength of WB signals corresponding to the particular ALKBHs were calculated by densitometry. The 
expression changes by 30% were considered as significant.
Viability assay. Exponentially growing cells at the density of 3 × 103 cells/well were seeded onto a 96-well 
plate, cultured for 18 h followed by the respective treatment of antraquinones or its derivatives in various concen-
trations or 34 nM RNA interference of ALKBH proteins, and then cultured for a an additional 48 h. Alamar Blue 
(Invitrogen) viability assay was performed according to manufacturer’s protocol: after 4 h incubation, emission at 
590 nm was measured with excitation at 560 nm using a scanning multiwall multimode spectrophotometer (DTX 
880, Beckman Coulter). The experiment was carried out at least three times, with three replicates for each inhibi-
tor concentration. After background subtraction, inhibition rates, IC50, values were calculated as the concentra-
tion of the component that inhibits cell growth by 50%. All the calculations were done using Origin 9.0 software.
flow cytometry. The Annexin V-FITC apoptosis detection kit (ApoAlert Annexin V-FITC Apoptosis Kit, 
TaKaRa) was used to detect apoptosis by flow cytometry. Cells were seeded at 6-well plates at concentration of 
5 × 105 cells/well, cultured for 18 h, and then the tested agent was applied for the indicated periods. Afterward, 
cells were washed with PBS, resuspended in binding buffer, and anti-Annexin V FITC-conjugated antibody and 
propidium iodide were added to 100 µl aliquots. The mixtures were incubated for 15 min at room temperature, 
supplemented with binding buffer to 500 µl, and processed using BD FACSCalibur (BD Biosciences). Data were 
analyzed in Flowing Software version 2.5.1 (Flowing Software, http://www.uskonaskel.fi/flowingsoftware).
Molecular modelling. All calculations were performed with the aid of Yasara Structure package (ver. 
17.1.28) using amber03 force-field. Initial structures of human ALKBH2 (3s57), ALKBH3 (2iuw), ALKBH5 
(4oct), ALKBH7 (4qkd) ALKBH8 (3thp) and FTO (4zs2), rice ALKBH1 (5xeg) and E.coli (3i3q) were adopted 
from the appropriate PDB records. Each of these structures carried 2OG and metal cation (either Mn or Fe) in 
the catalytic centre, while all other ligands were removed. The structures of ALKBH1, ALKBH4 and ALKBH6 
were modelled by homology on the basis PDB structures selected automatically by the combination of blast 
E-value, sequence coverage and structure quality. For each template, up to 5 alignments with the target sequence 
were used, and up to 50 different conformations were tested for each modelled loop. The resulting models were 
evaluated according to the structural quality (dihedral distribution, backbone and side-chain packing) and that 
with the highest score of these covering the largest part of the target sequence was used as the template for a 
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hybrid model, which was further iteratively improved with the best fragments (e.g. loops) identified among the 
highly-scored single-template models.
Molecular Docking was done for each protein/ligand pair with the aid of VINA algorithm with 128 rounds of 
flexible docking applied against 16 replicas of protein structures (each representing re-optimized random ensem-
ble of protein sidechain rotamers), and the resulting 2048 complexes were clustered with 2 Å threshold.
Statistical analyses. All analyses were performed using R software (version 3.3.0, www.r-project.org) with 
outliers and gplots packages. The significance level α of 0.05 was assumed in all statistical tests. The Shapiro-Wilk 
test was used to assess agreement of ALKBHs content with the Gaussian distribution. Because even after filtering 
of extreme values with the Grubbs’ test for putative outliers38 the vast majority of the distributions were found to 
be non-Gaussian, further analyses were based on the non-parametric methods. The statistical significance of the 
differences observed in protein levels were tested using Wilcoxon tests; the paired (signed-rank) or non-paired 
versions (rank-sum, Mann-Whitney) were applied accordingly to the hypothesis being tested (i.e. the differences 
concerning either individuals or whole group analysed, respectively). Correlation matrixes were calculated for 
the levels of seven proteins using Spearman’s rank correlation coefficients. Hierarchical cluster analysis of these 
matrixes was performed according to the Ward criterion. To estimate the correlation between ALKBHs levels 
and G/TNM parameters, analysis of variance (ANOVA) and post-hoc pairwise t-student test with Benjamini 
Hochberg adjustment was used. In that case, samples were divided into groups according to G or TNM param-
eters. Distribution analysis for each group was also performed. Normal distribution of data sets of examined 
proteins was not be excluded (Shapiro-Wilk test)39.
ethics approval and consent to participate. All participants were informed about the purpose of the 
study and gave their written informed consent. The study was approved by Warsaw Medical University Bioethical 
Committee permission for working with human tissues/tumours no. KBO/17/11 April 12th 2011. All research 
was performed in accordance with the relevant guidelines and regulations.
Data Availability
Please contact the corresponding author for all data requests.
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